Creation and validation of a bladder dysfunction symptom score for HTLV-1-associated myelopathy/tropical spastic paraparesis

Yamakawa, Natsuko; Yagishita, Naoko; Matsuo, Tomohiro; Yamauchi, Junji; Ueno, Takahiko; Inoue, Eisuke; Takata, Ayako; Nagasaka, Misako; Araya, Natsumi; Hasegawa, Daisuke; Coler-Reilly, Ariella; Tsutsumi, Shuntaro; Sato, Tomoo; Araujo, Abelardo; Casseb, Jorge; Gotuzzo, Eduardo; Jacobson, Steven; Martin, Fabiola; Puccioni-Sohler, Marzia; Taylor, Graham P.; Yamano, Yoshihisa; Japan Clinical Research Group on HAM/TSP.
Artículo en Inglés | ARCA | ID: arc-43044

Documentos relacionados

  1. Sensory neuronopathy heralding human T cell lymphotropic virus type I myelopathy.
  2. [HTLV-1-associated myelopathy].
  3. [Pathophysiology, treatment and biomarkers for HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)].
  4. Lived Experience of Human T-cell Leukemia Virus type-1 -Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): A Phenomenology Study.
  5. [The current and future approaches to the treatment of HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP)].
  6. Cerebral and spinal cord changes observed through magnetic resonance imaging in patients with HTLV-1-associated myelopathy/tropical spastic paraparesis: a systematic review.
  7. Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series.
  8. Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms.
  9. [HTLV-1: Recent topics in epidemiologic, basic and clinical research].
  10. Clinical and Public Health Implications of Human T-Lymphotropic Virus Type 1 Infection.